Polymorphisms of IKBKE gene are associated with major depressive disorder and panic disorder by Traks, T. et al.
Polymorphisms of IKBKE gene are associated with major
depressive disorder and panic disorder
Tanel Traks1,2,3, Kati Koido1,2, Roman Balõtšev4, Triin Eller4, Sulev Kõks2,5, Eduard Maron4,6,
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Abstract
Background: The immune system has been increasingly implicated in the devel-
opment of mood and anxiety disorders. Inhibitor of kappa light polypeptide
gene enhancer in B cells, kinase epsilon (IKBKE) gene encodes IKKe protein
that is involved in innate immunity, predominantly antiviral response genera-
tion. It also bears pro-inflammatory properties that could affect psychiatric out-
comes. In order to investigate the possible role of IKBKE gene in major
depressive disorder (MDD) and panic disorder (PD), we conducted a case–con-
trol genetic association study concerning these disorders. Methods: In all, 14
SNPs of IKBKE gene were genotyped in groups of 391 patients with MDD and
190 patients with PD together with respective 389 and 371 healthy control indi-
viduals. The given groups were further divided by gender for additional analy-
ses. Results: Substantial genetic associations were revealed between IKBKE
SNPs and MDD (multiple testing adjusted P < 0.05) and suggestive associations
in case of PD (Padj > 0.05). In addition, two SNPs that were only associated
with PD among males, also displayed significantly different allele frequencies
compared to PD females. This may indicate a specific role of these SNPs in
male PD, but caution should be applied here due to the small size of the stud-
ied PD males group. Conclusions: The results of this study confirm our initial
findings and indicate a possible role of IKBKE gene in mood and anxiety
disorders.
Introduction
Major depressive disorder (MDD) and panic disorder
(PD) are both common psychiatric disorders with a high
lifetime prevalence that is generally in range 10–15%
(Andrade et al. 2003; Kessler et al. 2005) and 3.7–5.1%
(Grant et al. 2006; Kessler et al. 2006), respectively, and
display a substantial female preponderance. Heritability
estimates of 37–38% for MDD (Sullivan et al. 2000; Ken-
dler et al. 2006) and around 40% for PD (Schumacher
et al. 2011) suggest a significant role for genetic factors in
the development of these diseases. Moreover, due to fre-
quent coexistence of MDD and PD (Johnson and Lydiard
1998), shared genetic risk factors can be expected (Hette-
ma et al. 2006; Mosing et al. 2009).
The classical paradigm relates MDD to impaired mono-
amine functioning in the central nervous system (CNS).
However, the potential contribution of the inflammatory
processes of innate immune system to depression is
continuously gaining more attention (Loftis et al. 2010;
Haroon et al. 2012). According to this concept, the
altered expression of various inflammatory mediators, for
example, interleukin (IL)-1, IL-6, and tumor necrosis fac-
tor (TNF)-alpha lead to changes in multiple aspects of
brain functioning and behavior, and are themselves sub-
jected to defective regulation by the hypothalamic-pitui-
tary-adrenal (HPA) axis that begins in the CNS (Capuron
and Miller 2011). To date, the genetic studies focusing on
candidate genes have predominantly implicated those that
are related to monoamine system and are expressed in
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the CNS as important contributors to MDD, including
the serotonin transporter (SLC6A4), brain-derived neuro-
trophic factor (BDNF), and tryptophan hydroxylase
(TPH2) genes (Lohoff 2010). Still, polymorphisms of
IL1B, TNF, C-reactive protein (CRP), and other genes
related to immune functions have repeatedly been associ-
ated with MDD (Bufalino et al. 2012). It is also notewor-
thy, that although only one among several genome-wide
association studies (GWAS) conducted to date has yielded
a locus of genome-wide significance (Kohli et al. 2011), a
study aiming to replicate previous candidate gene findings
by using GWAS data has provided confirmation to four
genes as possibly involved in MDD, three among which
are related to immune functions (Bosker et al. 2011). The
pathology of PD has been related to abnormally sensitive
fear network in the CNS (Gorman et al. 2000) and altera-
tions in the activity of the amygdala, the prefrontal cortex
and the hippocampus as well as various neurotransmitter
and neuroendocrine systems. The evidence for immune
alterations has been inconsistent, but shifts in lymphocyte
counts and cytokine levels were demonstrated (Park et al.
2005; Hoge et al. 2009). The majority of genetic studies
have focused on classic candidate genes related to seroto-
nin, cholecystokinin, dopamine, or adenosine systems,
and more recently, the genes involved in immune func-
tions have been added to this group of targets (Maron
et al. 2010).
Our previous study explored the single-nucleotide poly-
morphisms (SNPs) spanning the IL10 cytokine gene clus-
ter on chromosome 1q32 and revealed a single SNP
rs1539243 of the adjacent inhibitor of kappa light poly-
peptide gene enhancer in B cells, kinase epsilon (IKBKE)
gene to be associated with the development of MDD and
PD, although the result concerning MDD did not remain
statistically significant after correction for multiple testing
(Koido et al. 2010). This gene encodes inhibitor of jB
kinase e protein (IKKe) that is involved in innate antiviral
response (Sharma et al. 2003) and has also been identified
as oncogenic protein with elevated expression levels in
various types of cancers, including glioma (Boehm et al.
2007; Guo et al. 2009; Seo et al. 2009; Guan et al. 2011).
In addition to phosphorylating interferon regulatory fac-
tor 3 (IRF3) and IRF7 that induce antiviral type I inter-
feron (IFN) expression (Taniguchi and Takaoka 2002;
Sharma et al. 2003), IKKe also activates transcription fac-
tor NF-jB through different proposed mechanisms which
among other effects can cause the production of inflam-
matory cytokines (Shimada et al. 1999; Peters and Mania-
tis 2001; Adli and Baldwin 2006; Harris et al. 2006;
Mattioli et al. 2006; Sankar et al. 2006). Interestingly, the
genetic studies have associated IKBKE gene with inflam-
matory disorders, namely rheumatoid arthritis (RA) and
systemic lupus erythematosus (Dieguez-Gonzalez et al.
2009; Sandling et al. 2011). Considering these previous
findings and our own preliminary results, we selected
additional SNPs of IKBKE gene and conducted a more
thorough genetic association analysis to detect further
associations with MDD and PD.
Materials and Methods
Study sample
The participants of this study were recruited from Esto-
nian population: the patients from consecutive outpa-
tients and inpatients at the Clinic of Psychiatry of the
Tartu University Hospital and healthy control subjects by
a newspaper advertisement in Tartu, Estonia. The MDD
(n = 391; mean age SD 37.1  13.7 years; 114 male/277
female) and PD (n = 190; mean age SD
38.0  12.8 years; 44 male/146 female) diagnoses of unre-
lated patients were substantiated by a psychiatric inter-
view and verified by the Mini International
Neuropsychiatric Interview (MINI 5.0.0) based on DSM-
IV criteria (Sheehan et al. 1998). Controls (389 for MDD;
mean age SD 37.5  13.5 years; 129 male/260 female,
and 371 for PD; mean age SD 37.6  13.4 years; 111
male/260 female) were evaluated by the MINI and addi-
tional family history interview to exclude those with psy-
chiatric morbidity and a history of major psychiatric
disorders in first-degree relatives. All participants were of
white European ancestry and living in Estonia. The
patients were divided into MDD and PD subgroups
according to the primary diagnosis. MDD or PD was
considered primary if it was the principal diagnosis at the
time of the investigation and/or had an earlier onset in
the course of illness. Patients in MDD group were either
pure MDD or MDD comorbid with anxiety disorders.
Patients in PD group were either pure PD or PD comor-
bid with mood or other anxiety disorders. The control
group was the same for MDD and PD with an exception
of reducing the number of male subjects in control group
for PD to reflect the respective male/female ratio in PD
group. This matching was carried out to address the pos-
sible confounding effect of sex, as it has been shown that
different genetic factors could have a gender-specific
impact on the development of MDD or PD (Kendler
et al. 2001; Schumacher et al. 2011). Ultimately, there
were no significant differences in age or sex between the
patients and healthy controls. In order to conduct an
analysis by gender, the MDD and PD groups with their
respective controls were divided to male and female sub-
groups. The resulting groups consisted of 114 MDD
males and 277 MDD females with 129/260 controls and
44 PD males and 146 PD females with 111/260 controls.
The Ethics Review Committee on Human Research of the
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University of Tartu approved the study protocol. Each
subject provided a written informed consent prior to par-
ticipation.
SNP selection and genotyping
Our previous study revealed a single SNP rs1539243 of
the IKBKE gene that is positioned close to the IL10 cyto-
kine gene cluster to be associated with PD, and a sugges-
tive result was obtained with MDD (Koido et al. 2010).
To further elaborate this result, 13 additional SNPs of
IKBKE were selected for genotyping and rs1539243 was
also re-genotyped. The Tagger tool of Haploview v4.2
program was used to determine tagSNPs of IKBKE gene
region (de Bakker et al. 2005; Barrett et al. 2005), while
even spacing and possible effects on transcription factor
binding sites according to Genomatix ElDorado database
were considered as additional selection criteria. Genomic
DNA was extracted from the 9 mL blood samples and
Applied Biosystems SNPlexTM method was used for geno-
typing (Tobler et al. 2005).
Data analysis
The Haploview v4.2 program was used for allelic associa-
tion, linkage disequilibrium (LD), and haplotype analyses
between groups of patients and controls, and Hardy–
Weinberg equilibrium (HWE) calculations in control
group. The Confidence Intervals algorithm was applied to
define the haplotype blocks and the resulting blocks were
used in the haplotype association test. Comparison of
allele or haplotype frequencies between cases and controls
was done by chi-squared test. The statistical significance
threshold was set to 0.05 for all tests. Ten thousand per-
mutations were used to correct P values for errors of
multiple testing.
Results
In all, 14 SNPs of IKBKE gene were genotyped in groups
of 391 MDD and 190 PD patients and respective 389/371
control individuals. The allele frequencies of all SNPs
were similar to those reported within the HapMap Project
data for individuals with ancestry from Northern and
Western Europe (CEU cohort).
Allelic association analysis
The results of allelic association analysis for MDD and
PD are presented in Table 1. SNP allele frequencies in
MDD group compared to control group demonstrated
statistically significant differences for two SNPs. Namely,
rs2274902 and rs1930437 (P values, odds ratios (OR),
and 95% confidence intervals (CI) were 0.0013, 0.72
(0.59–0.88) and 0.0007, 1.41 (1.16–1.73), respectively)
and these results withstood the correction for multiple
testing that involved ten thousand permutations (respec-
tive P values 0.0291 and 0.0160). Three SNPs showed sta-
tistically significant associations with PD – rs1539243,
rs1953090, rs11117909, but the respective P values of
0.0112 (OR 1.50 (CI: 1.09–2.05)), 0.0339 (OR 0.73 (CI:
0.55–0.98)), and 0.0256 (OR 1.49 (CI: 1.05–2.13)) did not




















1 rs1930438 50 near gene G/A 16.7 15.7 0.305 0.581 20.6 15.9 3.805 0.051
2 rs17020312 50 UTR A/C 4.3 4.0 0.129 0.720 4.2 3.9 0.06 0.807
3 rs2274902 Intron 2 G/A 41.6 49.7 10.33 0.001* 47.4 49.2 0.333 0.564
4 rs1930437 Intron 2 T/G 55.8 47.1 11.574 <0.001* 49.5 48.0 0.227 0.633
5 rs1539243 Exon 4 C/T 17.6 16.0 0.7 0.403 22.0 15.8 6.436 0.011
6 rs1953090 Intron 4 A/C 30.8 28.5 0.996 0.318 23.0 29.0 4.501 0.034
7 rs11117909 Intron 6 G/A 12.7 12.2 0.084 0.772 16.3 11.5 4.981 0.026
8 rs2297543 Intron 8 G/A 22.4 20.4 0.901 0.343 18.3 21.0 1.177 0.278
9 rs17021877 Exon 10 G/A 0.8 1.0 0.321 0.571 0 1.0 3.638 0.057
10 rs11118092 Intron 13 C/T 35.8 38.0 0.778 0.378 36.5 37.4 0.091 0.763
11 rs11118132 Intron 15 G/C 33.7 32.3 0.355 0.552 33.3 32.6 0.067 0.797
12 rs2336940 Intron 18 G/C 15.9 14.8 0.355 0.551 17.2 15.0 0.874 0.350
13 rs3748022 Exon 22 C/T 17.6 17.8 0.019 0.891 16.1 18.5 1.054 0.305
14 rs15672 30 UTR G/A 48.0 50.0 0.647 0.421 45.8 49.3 1.263 0.261
MDD, major depressive disorder; PD, panic disorder; MAF, minor allele frequency.
P values ≤0.05 are highlighted in bold.
*Designates P values ≤0.05 after 10,000 permutations.
ª 2015 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. Brain and Behavior, doi: 10.1002/brb3.314 (3 of 9)
T. Traks et al. IKBKE Genetic Associations with MDD and PD
survive the corrections for multiple testing. Rs1930438
showed a trend toward association with PD, but narrowly
missed the significance threshold.
Additional analysis by gender resulted in no significant
associations in male MDD group and two associations in
female MDD group that concerned the same SNPs as in
the whole MDD group – rs2274902 and rs1930437. The
respective P values of 0.0044 (OR 0.70 (CI: 0.55–0.87))
and 0.0037 (OR 1.43 (CI: 1.12–1.82)) did not remain sig-
nificant after permutations. In male PD group, two signif-
icant results were evident, involving rs1953090 and
rs2297543 with respective P values of 0.0013 (OR 0.34
(CI: 0.18–0.67)) and 0.0456 (OR 0.49 (CI: 0.24–1)). Asso-
ciation with the former SNP was present in whole PD
group and remained significant after permutations
(P = 0.0242). The female PD group produced one associ-
ation for rs11117909 (P = 0.0485, OR 1.51 (CI: 1–2.28))
that was associated in whole PD group, and the other for
rs1930438 (P = 0.0449, OR 1.45 (CI: 1.01–2.1)). These
did not remain significant after permutations. Addition-
ally, rs1539243, that was associated in whole PD group,
showed a trend toward association (P = 0.0532).
Haplotype analysis
Four haplotype blocks were formed by 10 of the geno-
typed SNPs (Fig. 1). Two haplotypes of Block 1 (consist-
ing of rs1930438, rs2274902, and rs1930437) were
associated with MDD (Table 2). Specifically, haplotypes
GAT and GGG with respective P values of 0.0015 (OR
0.72 (CI: 0.59–0.88)) and 0.0022 (OR 1.38 (CI: 1.12–
1.70)) that remained below the significance threshold
after corrections for multiple testing (permutation P val-
ues 0.0332 and 0.0479, respectively). While the frequency
of the GAT haplotype was lower among MDD patients
(41.3%) compared to control individuals (49.3%) thus
indicating a possible protective effect, the frequencies of
GGG haplotype were reversed (38.9% in MDD group and
31.5% in control group), thereby suggesting a possible
promoting effect, that is, risk haplotype. Two haplotypes
Table 2. Results of Block 1 haplotype analysis in MDD group.
rs1930438 rs2274902 rs1930437
Haplotype frequencies (%)
Chi square P valueTotal Cases Controls
G A T 45.3 41.3 49.3 10.046 0.002*
G G G 35.3 38.9 31.5 9.348 0.002*
A G G 16.0 16.5 15.5 0.302 0.583
G G T 3.3 3.0 3.5 0.374 0.541
MDD, major depressive disorder.
P values ≤0.05 are highlighted in bold.
*Designates P values ≤0.05 after 10,000 permutations.
Figure 1. Genotyped SNPs of IKBKE gene
region. The image of LD pattern was
generated using the Haploview v4.2
program and black boxes indicate
haplotype blocks in MDD association
analysis.
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of Block 2 consisting of rs1539243 and rs1953090 were
associated with PD (Table 3). Haplotype CC was protec-
tive (22.7% in PD group and 28.9% in control group,
P = 0.0272, OR 0.72 (CI: 0.54–0.97)), whereas TA was a
risk haplotype (21.6% in PD group and 15.8% in control
group, P = 0.0154, OR 1.47 (CI: 1.08–2.02)), although
these results did not survive the correction for multiple
testing. Alternatively, in MDD analysis this block was
formed by rs1953090 and rs11117909 (Fig. 1). Haplotype
CG of Block 4 consisting of rs3748022 and rs15672 also
produced a suggestive result as a risk haplotype (38.1% in
PD group and 32.1% in control group, P = 0.0441, OR
1.30 (CI: 1.01–1.69)), but again, this did not survive the
correction for multiple testing (Table 3).
When analyzing by gender, no associations were pres-
ent in male MDD group and two associations that coin-
cided with the ones in whole MDD group were present in
female MDD group. Namely, these concerned the haplop-
types GAT and GGG of Block 1 with respective P values
of 0.0085 (OR 0.72 (CI: 0.57–0.92)) and 0.0113 (OR 1.39
(CI: 1.08–1.78)), and did not remain significant after per-
mutations. In male and female PD groups rs1539243 and
rs1953090 did not form a haplotype block. Therefore, the
Block 2 associations present in whole PD group cannot
be compared with the results from these subgroups. One
haplotype association was evident in male PD group
(P = 0.0389, OR 2.04 (CI: 1.03–4.05)). It involved the
haplotype GCC of Block 3 that is formed by rs2297543,
rs11118092, and rs11118132 and did not remain signifi-
cant after permutations. No further associations were
detected in male or female PD groups.
Discussion
The findings of our previous study suggested a possible
role for IKBKE gene in PD and MDD (Koido et al.
2010). Thus, additional SNPs of IKBKE gene were geno-
typed, resulting in the detection of several allelic and hap-
lotype associations in both MDD and PD study groups.
Two single marker and two haplotype associations were
identified for MDD and these affirmingly survived the
correction for multiple testing. Three single marker and
three haplotype associations were identified for PD,
although these did not remain significant when the cor-
rection for multiple testing was applied. However, it
should be noted, that there were roughly half as many
PD patients in the analysis as MDD patients and given a
larger sample size, the similar allele and haplotype fre-
quencies could result in more significant results. The for-
merly associated SNP rs1539243 (Koido et al. 2010)
produced a weaker association for PD in current analysis
and did not meet the significance threshold in case of
MDD. This contrast can be reasoned by the recognition
that the present control and patient groups were not
identical to those that were assembled previously. While
the majority of samples were unchanged, a significant
portion of controls and patients were omitted and
replaced by new samples. When analyzing by gender, a
number of differences in allelic and haplotype associations
occurred. Despite this, in MDD males and females, the
associated allele and haplotype frequencies were actually
similar, and the observed discrepancies could be attrib-
uted to differences in sample sizes. The same can be
argued for PD subgroups with the exception of SNP
rs2297543 (G allele case/control frequencies (%) in PD
males vs. PD females: 87.2/77 vs. 80.1/79.8) together with
Block 3 haplotype GCC (19.1/10.4 vs. 13.5/12.5), and
most notably rs1953090 (A allele: 86.4/68.5 vs. 74.1/72.1).
These displayed significant differences only in PD males
compared to their controls. This may indicate that these
polymorphisms specifically influence PD susceptibility in
males, but insists caution when considering the small sizes
of PD males and their control groups.
The IKBKE gene is composed of 22 exons and is
located in chromosomal region 1q32. According to avail-
able literature, the genetic polymorphisms of this region
have been associated with both MDD and PD. Candidate
gene studies have implied arginine vasopressin receptor
1B (AVPR1B) and plexin A2 (PLXNA2) genes as possible
contributors to these diseases (van West et al. 2004; Wray
Table 3. Results of Block 2 and Block 4 haplotype analysis in PD group.
Block 2 Block 4 Haplotype Frequencies (%)
Chi square P valuers1539243 rs1953090 rs3748022 rs15672 Total Cases Controls
C A 55.3 55.4 55.3 0.0 0.986
C C 26.8 22.7 28.9 4.876 0.027
T A 17.8 21.6 15.8 5.875 0.015
C A 48.2 45.8 49.3 1.239 0.266
C G 34.1 38.1 32.1 4.051 0.044
T G 17.7 16.1 18.6 1.088 0.297
PD, panic disorder.
P values ≤0.05 are highlighted in bold.
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et al. 2007; Keck et al. 2008) and a recent GWAS proposed
plakophilin 1 (PKP1) gene for this role in PD, although
the result was not subsequently replicated in an indepen-
dent sample (Otowa et al. 2009, 2010). Genetic linkage
studies have resulted in modest evidence for 1q involve-
ment in MDD and PD (Gelernter et al. 2001; Zubenko
et al. 2003) and more specifically 1q32 in PD (Smoller
et al. 2001). Additionally, this region has emerged as one
of the susceptibility loci for other psychiatric disorders
such as bipolar disorder and schizophrenia (Detera-Wad-
leigh et al. 1999; Gurling et al. 2001). Taken together,
these findings highlight 1q32 as one of the potential sus-
ceptibility loci for MDD and PD, and the IKBKE variants
within it could represent some of the truly causal factors.
IKKe kinase is predominantly expressed in immune
cells and can be activated by double-stranded (ds) DNA,
dsRNA, and viral infection (Shimada et al. 1999; Fitzger-
ald et al. 2003; Hemmi et al. 2004; Ishii et al. 2006) as
well as inflammation-inducing lipopolysaccharide (LPS)
and cytokines (Shimada et al. 1999; Kravchenko et al.
2003; Hemmi et al. 2004). On the one hand, this leads to
subsequent activation of IRF3 and IRF7 that induce type
I IFN expression which is associated with anti-viral
response (Taniguchi and Takaoka 2002; Sharma et al.
2003), but has also been implicated in sustaining chronic
inflammation (Lee et al. 2009). The other notable effect is
the activation of NF-jB, a key regulator of immune
responses to infection and inflammatory processes, and
this can elevate the production of inflammatory cytokines
(Shimada et al. 1999; Sankar et al. 2006). Of note, NF-jB
itself has in turn been identified as an activator of IKKe
(Wang et al. 2005). Considering these relations between
IKKe and inflammatory mediators and the role of inflam-
matory processes in mood and anxiety disorders, it can
thus be proposed that in the event of altered IKKe mRNA
expression or protein functioning it may contribute to
impaired immune regulation and therefore to the devel-
opment of these psychiatric conditions. For instance, it
has been demonstrated that NF-jB signaling is a key to
developing depressive-like behaviors under chronic stress
(Koo et al. 2010), and hence there is a possibility of mod-
ulation by IKKe. Another supportive finding to this
notion is the detection of IKKe in fibroblast-like synovio-
cytes of RA and osteoarthritis patients that suggests its
possible involvement in chronic inflammatory conditions
(Sweeney et al. 2005). Interestingly, the intronic SNP
rs1930437 that was associated with MDD in this study
affects the binding site of c-Rel, a transactivating compo-
nent of a dimeric NF-jB, as evident from JASPAR tran-
scription factor database search by ConSite web-based
tool (Sandelin et al. 2004). Namely, the substitution of
allele G for allele T disrupts the c-Rel binding sequence
and could possibly abolish the enhancer function of NF-
jB on IKKe mRNA transcription. The G allele was signifi-
cantly more frequent among MDD patients compared to
control subjects (55.8 vs. 47.1%) and this may indicate a
more active IKBKE transcription that promotes inflam-
matory mediators and eventually influences psychiatric
outcomes. The remaining four associated SNPs similarly
do not cause changes in the peptide sequence of IKKe
protein. It is possible that these SNPs are in LD with
other polymorphisms that affect IKBKE transcription (for
rs2274902 this could be the above described rs1930437)
or with nonsynonymous mutations that may exist in the
studied population as rare variants. For example, the
three SNPs associated with PD are located in the region
of exons that encode the kinase domain of IKKe (Shimad-
a et al. 1999) and polymorphisms modifying its structure
might be reflected in the observed genetic associations.
The presented findings should be interpreted with cau-
tion due to methodological limitations. The sample sizes
were small, especially the PD patients group. Both MDD
and PD groups contained subjects with comorbid diagno-
ses. Different SNPs were associated with MDD compared
to PD and one possibility to interpret this is that distinct
genetic or functional changes in IKBKE can influence the
development of MDD and PD. However, this could also
indicate false positive results, especially in case of PD, as
they failed the correction for multiple testing. Finally, the
majority of the sample and one genotyped SNP over-
lapped with our previous report (Koido et al. 2010), and
thus it cannot be considered as an independent replica-
tion study, hindering the significance of current findings.
Conclusion
Our study contributes to general research that explores the
role of innate immune inflammatory processes in MDD
and PD. The presented results confirm our initial findings
and indicate a possible role of IKBKE gene in mood and
anxiety disorders. Several single marker and haplotype
associations were evident for both MDD and PD, although
the ones concerning MDD were more convincing. How-
ever, the noticeable limitations of this investigation should
be considered when interpreting this data. Therefore, repli-
cation genetic studies in different samples along with func-
tional analyses are required to confirm the relevance of
current findings. By identifying the various genetic factors
and achieving a more thorough understanding of the
immune system in MDD and PD, this could ultimately
lead to advancements in prevention and treatment.
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